Ixico Regulatory News (IXI)

13 Nov 2008 07:00



13 November 2008

Phytopharm plc

Board Changes

GODMANCHESTER, Cambridgeshire, U.K.- The Board of Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") today announces that the Company has received notice of termination of employment contract from Daryl Rees, Chief Executive Officer, and Piers Morgan, Chief Financial Officer. They cease to be Directors of the Company with immediate effect.

A further announcement in respect of the Company's future direction and management will be made in due course.

The Company's preliminary results will be announced on 27 November 2008 as planned.

 -Ends-

Notes to Editors

Phytopharm plc

Phytopharm is a pharmaceutical development and functional food company. Our products are developed from medicinal plants, thereby reducing the development risk, cost and time to market. As a virtual company, Phytopharm's business model is centred on a lean cash burn with all laboratory, manufacturing and clinical work out-sourced to specialists, while core competencies such as strategy and management are maintained in-house. Close collaboration with charitable organisations enhances our interaction with worldwide specialists and accelerates our development programmes increasing their value.

For further information about Phytopharm please see our website at http://www.phytopharm.com